Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FS 118

Next Previous
Drug Profile

FS 118

Alternative Names: FS-118; LAG-3/PD-L1 Bispecific Antibody

Latest Information Update: 12 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator f-star
  • Developer F-star Therapeutics; Merck KGaA
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma; Head and neck cancer; Non-small cell lung cancer
  • No development reported Haematological malignancies; Solid tumours

Most Recent Events

  • 07 Dec 2024 Efficacy and adverse events data from phase-II trial in Diffuse large B cell lymphoma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
  • 07 Nov 2024 F-star Therapeutics completes phase-II trial in Non-small cell lung cancer and Diffuse large B cell lymphoma (First-line therapy, Late-stage disease) in Bulgaria and France(IV) (EUCT2021-003406-47)
  • 31 Jul 2024 invoX Pharma Limited terminates a phase I trial in Haematological malignancies (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) (IV) in USA, due to business decision(NCT03440437)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top